Trial · NCT04602000
Adverse events140
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 140
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukopenia | Blood and lymphatic system disorders | CT-P59 40 mg/kg Group (Part 1) | 3 | 105 | 3 |
| other | Leukopenia | Blood and lymphatic system disorders | CT-P59 80 mg/kg Group (Part 1) | 3 | 110 | 3 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo Group (Part 1) | 0 | 110 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | CT-P59 40 mg/kg Group (Part 2) | 6 | 652 | 6 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo Group (Part 2) | 12 | 650 | 12 |
| other | Thrombocytosis | Blood and lymphatic system disorders | CT-P59 40 mg/kg Group (Part 1) | 3 | 105 | 3 |
| other | Thrombocytosis | Blood and lymphatic system disorders | CT-P59 80 mg/kg Group (Part 1) | 1 | 110 | 1 |
| other | Thrombocytosis | Blood and lymphatic system disorders | Placebo Group (Part 1) | 2 | 110 | 2 |
| other | Thrombocytosis | Blood and lymphatic system disorders | CT-P59 40 mg/kg Group (Part 2) | 11 | 652 | 11 |
| other | Thrombocytosis | Blood and lymphatic system disorders | Placebo Group (Part 2) | 5 | 650 | 5 |
| other | Cystitis | Infections and infestations | CT-P59 40 mg/kg Group (Part 1) | 3 | 105 | 3 |
| other | Cystitis | Infections and infestations | CT-P59 80 mg/kg Group (Part 1) | 2 | 110 | 2 |
| other | Cystitis | Infections and infestations | Placebo Group (Part 1) | 0 | 110 | 0 |
| other | Cystitis | Infections and infestations | CT-P59 40 mg/kg Group (Part 2) | 0 | 652 | 0 |
| other | Cystitis | Infections and infestations | Placebo Group (Part 2) | 1 | 650 | 1 |
| other | Alanine aminotransferase increased | Investigations | CT-P59 40 mg/kg Group (Part 1) | 0 | 105 | 0 |
| other | Alanine aminotransferase increased | Investigations | CT-P59 80 mg/kg Group (Part 1) | 1 | 110 | 2 |
| other | Alanine aminotransferase increased | Investigations | Placebo Group (Part 1) | 1 | 110 | 1 |
| other | Alanine aminotransferase increased | Investigations | CT-P59 40 mg/kg Group (Part 2) | 19 | 652 | 22 |
| other | Alanine aminotransferase increased | Investigations | Placebo Group (Part 2) | 31 | 650 | 34 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04602000/events